Effects of Levosimendan on Microcirculation in Septic Shock
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The present study was conducted as a prospective, randomized, controlled study to:
- investigate the effects of a combination of levosimendan and inhaled nitric oxide on systemic hemodynamics and microcirculation in patients with catecholamine-dependent septic shock;
- test the hypothesis that levosimendan plus inhaled nitric oxide may be effective in restoring microvascular function in septic shock.
| Condition | Intervention | Phase |
|---|---|---|
|
Septic Shock |
Drug: Levosimendan Drug: dobutamine |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Levosimendan and Inhaled Nitric Oxide for Resuscitating the Microcirculation in Septic Shock. A Randomized Controlled Trial |
- Systemic hemodynamic and Microcirculatory flow index of small and medium vessels (MFI) [ Time Frame: over a period of 36 hrs from the time of randomization ] [ Designated as safety issue: No ]
- Acid-base homeostasis [ Time Frame: over a period of 36 hrs from the time of randomization ] [ Designated as safety issue: No ]
- Oxygen transport variables [ Time Frame: over a period of 36 hrs from the time of randomization ] [ Designated as safety issue: No ]
- Functional capillary density (mm/mm2) (FCD) [ Time Frame: over a period of 36 hrs from the time of randomization ] [ Designated as safety issue: No ]
- De Backer score [ Time Frame: over a period of 36 hrs from the time of randomization ] [ Designated as safety issue: No ]
- Perfused Vessel Density (PVD) (mm/mm2) [ Time Frame: over a period of 36 hrs from the time of randomization ] [ Designated as safety issue: No ]
- Proportion of Perfused vessels (%) (PPV) [ Time Frame: over a period of 36 hrs from the time of randomization ] [ Designated as safety issue: No ]
| Enrollment: | 40 |
| Study Start Date: | November 2007 |
| Study Completion Date: | April 2009 |
| Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: levosimendan |
Drug: Levosimendan
Intravenous administration of Levosimendan 0,2 µg•kg-1•min-1 for 24 hrs followed by the addition of 35 ppm of inhaled nitric oxide
|
| Active Comparator: Control |
Drug: dobutamine
Intravenous administration of dobutamine 5 µg•kg-1•min-1 for 36 hrs. At the end of the first 24 hrs drug infusion, inhaled nitric oxide at the concentration of 35 ppm will be added for further 12 hrs.
|
Detailed Description:
40 septic shock patients requiring norepinephrine to maintain mean arterial pressure between 65 and 75 mmHg despite adequate volume resuscitation will be enrolled in the study. After an initial hemodynamic resuscitation aimed at achieve a mean arterial pressure between 65 and 75 mmHg and a mixed venous oxygen saturation (SvO2) ≥ 65%, patients will be randomly allocated to be treated with either a) intravenous administration of levosimendan 0.2 µg∙kg-1∙min-1 for 24 hrs, b)intravenous administration of dobutamine 5 µg∙kg-1∙min-1 for 36 hrs(control; each n = 20). At the end of the first 24 hrs of the study period, both groups will receive inhaled nitric oxide at the concentration of 35 ppm for further 12 hrs. In all patients norepinephrine was titrated to maintain mean arterial pressure between 65 and 75 mmHg. Data from right heart catheterization and sublingual microvascular network will be obtained just before randomization (baseline) and then after 24 and 36 hours.
The sublingual microvascular network will be studied using the sidestream dark field (SDF) imaging. The device will be applied on the lateral side of the tongue, in an area approximately 2-4 cm from the tip of the tongue. Sequences of 10 secs from eight adjacent areas will be recorded on disk using a personal computer. These sequences will be later analyzed by an investigator blinded to the patient's diagnosis and therapy.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinical diagnosis of Septic shock
- Vasopressor support to maintain mean arterial pressure (MAP) between 65 and 75 mmHg despite adequate volume resuscitation (pulmonary artery occlusion pressure = 13-18 mmHg and central venous pressure = 8-12 mmHg)
Exclusion Criteria:
- Pregnancy
- Age < 18 years
- Ventricular outflow tract obstruction
- Mitral valve systolic anterior motion
Contacts and Locations| Italy | |
| Departement of Anesthesiology and Intensive Care of the University of Rome "La Sapienza" Viale del Policlinico 155 | |
| Rome, Italy, 00161 | |
| Principal Investigator: | Andrea Morelli, M.D. | University of Rome "La Sapienza", Department of Anesthesiology and Intensive Care |
More Information
No publications provided by University of Roma La Sapienza
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Andrea Morelli, University of Rome "La Sapienza" |
| ClinicalTrials.gov Identifier: | NCT00800306 History of Changes |
| Other Study ID Numbers: | 1102 |
| Study First Received: | December 1, 2008 |
| Last Updated: | October 14, 2009 |
| Health Authority: | Italy: Ethics Committee |
Keywords provided by University of Roma La Sapienza:
|
sepsis septic shock microcirculation levosimendan |
dobutamine inotropes inhaled nitric oxide |
Additional relevant MeSH terms:
|
Shock Shock, Septic Pathologic Processes Sepsis Infection Systemic Inflammatory Response Syndrome Inflammation Simendan Dobutamine Nitric Oxide Cardiotonic Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Sympathomimetics |
Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Adrenergic beta-1 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Protective Agents Bronchodilator Agents Anti-Asthmatic Agents Respiratory System Agents Free Radical Scavengers Antioxidants |
ClinicalTrials.gov processed this record on June 18, 2013